Login to Your Account


HCV drug access remains varied and oft-restricted in Europe

By Michael Fitzhugh
Staff Writer

Friday, April 21, 2017

AMSTERDAM – Despite the transformative impact of direct-acting antivirals (DAAs) in treating hepatitis C virus (HCV), reimbursement for the drugs still faces "considerable restrictions" in Europe, according to research presented Thursday at the International Liver Congress, suggesting that an early challenge for key drugmakers in the space, such as Gilead Sciences Inc. and Abbvie Inc., still endures.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription